The nephroprotective effect of metformin with cisplatin in bladder cancer: randomized clinical trial
- 3 May 2025
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (11) , 3611-3624
Abstract
Purpose Cisplatin-based combination chemotherapy is the mainstay treatment strategy in various forms of carcinomas and sarcomas. However, its dosage and therapeutic efficacy are significantly limited by its nephrotoxicity. Based on metformin renal benefits in different studies, the study aims to determine safety and the potential nephroprotective effect of metformin when used with cisplatin in patients with bladder cancer. Methods This was a prospective, randomized, parallel, controlled, open-label study in which 78 chemotherapy naïve bladder cancer patients aged 18–65 years and would receive gemcitabine/cisplatin regimen were selected and randomly assigned to treatment or control group in 1:1 allocation. Both groups were receiving cisplatin standard-of-care regimen, whereas metformin (500 mg, twice daily) was added to the treatment group's regimen only. Patients were prospectively followed up for four cycles of gemcitabine/cisplatin with assessment of renal function tests, serum neutrophil gelatinase-associated lipocalin (NGAL), cystatin-c, and metformin's adverse effects. Results Serum creatinine, serum NGAL, and cystatin-C significantly increased in the control group only (P < 0.001). Estimated glomerular filtration rate (eGFR) significantly declines in the control group only (P < 0.001). On the contrary, serum NGAL significantly improved in the treatment group (P = 0.02) with stable and normal mean value of serum creatinine, eGFR, and cystatin-C without a concomitant significant increase in adverse events, such as hypoglycemia, gastrointestinal symptoms, or weight loss compared to the control group. Conclusion Metformin prevented renal damage and deterioration in kidney function in cisplatin-treated patients. Therefore, it is a promising agent in reducing cisplatin-induced nephrotoxicity. The study was registered in ClinicalTrials.gov on December, 16, 2023, Identifier Number NCT06215976.Keywords
Funding Information
- This study received a financial research support for teaching assistants from Faculty of Pharmacy, Cairo University
This publication has 44 references indexed in Scilit:
- Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by Ghrelin in Male MiceEndocrinology, 2013
- Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trialClinical Nutrition, 2013
- Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluationOncology Reports, 2013
- Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Renal Tubular Cell Injury by Suppressing Reactive Oxygen Species Generation via Reducing Receptor for AGEs (RAGE) ExpressionHormone and Metabolic Research, 2012
- Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens2011
- A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patientsNephrology Dialysis Transplantation, 2008
- Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal functionInternational Journal Of Clinical Practice, 2007
- Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitisHepatology Research, 2007
- Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.Journal of Clinical Oncology, 1985
- Combination antiemetic therapy in cisplatin-induced nausea and vomitingCancer, 1985